Advertisement
UK markets close in 1 hour 52 minutes
  • FTSE 100

    8,214.33
    -33.46 (-0.41%)
     
  • FTSE 250

    20,280.56
    -82.87 (-0.41%)
     
  • AIM

    765.73
    -2.30 (-0.30%)
     
  • GBP/EUR

    1.1838
    +0.0001 (+0.01%)
     
  • GBP/USD

    1.2633
    -0.0054 (-0.42%)
     
  • Bitcoin GBP

    48,817.62
    +461.72 (+0.95%)
     
  • CMC Crypto 200

    1,274.46
    -9.32 (-0.73%)
     
  • S&P 500

    5,457.12
    -12.18 (-0.22%)
     
  • DOW

    38,992.74
    -119.42 (-0.31%)
     
  • CRUDE OIL

    80.92
    +0.09 (+0.11%)
     
  • GOLD FUTURES

    2,310.80
    -20.00 (-0.86%)
     
  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     
  • HANG SENG

    18,089.93
    +17.03 (+0.09%)
     
  • DAX

    18,068.44
    -109.18 (-0.60%)
     
  • CAC 40

    7,577.06
    -85.24 (-1.11%)
     

Guardant Health Stock Jumps. Blood Test for Cancer Moves Toward FDA Approval.

Guardant Health Stock Jumps. Blood Test for Cancer Moves Toward FDA Approval.

Shares of Guardant Health were rising sharply after the cancer company said a Food and Drug Administration advisory committee recommended the agency approve the company’s blood test for colorectal cancer screening. The test, Shield, is for people 45 and older who are at average risk for the disease, according to the release. “The recommendation signals the advisory committee panel’s consensus on Shield’s safety and effectiveness with its proposed intended use, and their conclusion that its benefits as a primary non-invasive screening option outweigh any potential risks,” according to the release.